Established through a generous $5.4 million gift from businessman and philanthropist Louis B. Thalheimer, the Fund provides seed funding for vital proof-of-concept and validation studies of valuable technologies at Johns Hopkins. Recipients are awarded $25,000 to $100,000 to conduct work over a period of up to nine months.

Application Deadline: Early April
Award Timing: May/June announcement and award

Applications are closed at this time.


To be considered, your application must meet the following criteria:

  1. Your technology must be formally disclosed to the Johns Hopkins Technology Ventures office and assigned a case number (e.g. C12345) Disclose an invention here:
  2. The invention must not be subject to any pre-existing exclusive licenses, non-exclusive licenses, or options.
  3. At least one investigator must have a full, joint, or courtesy faculty appointment at Johns Hopkins University.
  4. The application must not exceed 5 pages excluding the cover page.

Please note: The Louis B. Thalheimer Fund for Translational Research is an evergreen fund. When Thalheimer-funded technologies are successfully licensed, a portion of the Hopkins’ license revenue (twice the award amount) is repaid to the Thalheimer Fund to support future projects. Therefore, if a technology receives a $100,000 award, $200,000 is repaid to the Thalheimer Fund before any revenues are distributed to Johns Hopkins, including inventors.

Application Components

A. Header/Applicant Information (Cover page).

  • The principal investigator’s name and contact information
  • Title of the project
  • The JHTV case number for the technology (ex. C12345)
  • The total amount of funding received to date
  • The total amount of funding requested
  • This information should appear as a stand-alone Cover page

B. Technology Description, Status, and Intellectual Property

  • A detailed description of the associated Technology should be provided. The description should focus on how the Technology is unique/novel in its approach to solve an important commercial problem relative to other approaches in the scientific literature and other commercial products.
  • Describe the status of the Technology’s development including the studies completed and the conclusions derived.
  • Any preliminary data or other results suggesting that the Technology is likely to work as predicted should be included.
  • Describe the intellectual property secured for the Technology and strategies for strengthening the Technology’s intellectual property portfolio.

C. Application of Technology as a Product and Commercial Market Assessment

  • Describe potential commercial products or services that could be based on the technology.
  • Describe how these products will solve a problem in the market and describe the overall importance of solving that problem.
  • Include a description of the customer who will buy the product or service and a brief summary of the size of the market opportunity that these customers represent.
  • Include a description of the value proposition (ideally quantified) that these products will bring to customers – cost savings, time savings, convenience, improved outcomes, etc.
  • Outline a general description of the technology’s competitive advantages over competing products and services. If possible, include a chart that compares key features of your product with competing products that are either on the market or in development.

D. Commercialization Pathway and Risk Assessment

  • Provide an overview of the overall steps/milestones needed to commercialize the Technology (beyond the funding) including how long it will take and how much it will cost to achieve key milestones.
  • Describe how you see the technology being licensed, such as via startup company or a license to a corporate entity. In either case, identify potential commercial partners and the level of interest those partners have in the technology, if any.
  • The major risks of failure (beyond the proposed project, e.g., technology risk, market risk, etc.) should also be described along with the applicant’s plans to manage that risk, i.e., what would be done if the proposed commercialization approach was not successful.

E. Project Description, Milestones, and Detailed Budget/Justification.

  • Include a summary of the proposed project and the anticipated milestones and a clear timeline. The project timeline should not exceed 9 months.
  • Describe how each of the milestones leads to a clear demonstration or validation of the technology for the proposed commercial purpose and/or significantly advances the technology along the commercialization pathway. Milestones must be quantifiable and measurable so it will be obvious when they have been successfully, or unsuccessfully, met.
  • A budget of the costs required to conduct the project should be provided.
  • A justification the significant project costs should be provided.
  • Please note that if the research plan is slated to be conducted during the regular academic year, you may not include faculty salary support. Additionally, indirect costs are not covered by the Thalheimer Fund and should not be included in the proposal’s budget.

F. Letters of support (Optional)

  • Confirm the technology as impactful and leading edge
  • Validate a commercial market need
  • Indicate a specific willingness to assist, use, license or fund
  • Indicate an increased likelihood technical success and commercialization

Review Process

All applications will be reviewed by a committee comprising relevant industry members as well as faculty and staff.  Evaluation of proposals will be on the basis of innovation and scientific merit, prospective market impact, technical feasibility, and commercialization potential.  Finalists will be notified in early April and must prepare for an in-person presentation in May. The projected award date is July 1, 2022. Please plan availability and project timelines accordingly.

Reporting Requirements

Award recipients will be required to prepare a midterm report on project activities and results to date, progress toward meeting midterm milestones, accounting of expenditures charged to the award and details on the proposed commercialization plan. The midterm report will include an in-person review meeting with the Thalheimer Foundation in December. A final report will be due within 30 days of completion of the project in the form of a 1-page summary of results and commercialization efforts to date. Annual post-award updates are expected as the technology progresses toward commercialization.

Read our Translational Funding Application Guide


For information about this and other translational funding

Brian Stansky

Senior Director, FastForward